3 April 2024 in Diabetes Care
OBJECTIVE: To evaluate the association of insulin injection adherence, smart insulin pen engagement, and glycemic control using real-world data from 16 countries from adults self-administering basal insulin degludec and bolus insulin with a smart insulin pen (NovoPen 6 or NovoPen Echo Plus) alongside continuous glucose monitoring (CGM). RESEARCH DESIGN AND METHODS: Data were aggregated over 14-day periods. Treatment adherence was defined according to the number of missed basal and missed bolus insulin doses and smart pen engagement according to the number of days with data uploads. RESULTS: Data from 3,945 adults, including 25,157 14-day periods with ≥70% CGM coverage, were analyzed. On average, 0.2 basal and 6.0 bolus insulin doses were missed over 14 days. The estimated probability of missing at least one basal insulin dose over a 14-day period was 17.6% (95% CI 16.5, 18.7). Missing one basal or bolus insulin dose per 14 days was associated with a significant decrease in percentage of time with glucose levels in range (TIR) (3.9–10.0 mmol/L), of −2.8% (95% CI −3.7, −1.8) and −1.7% (−1.8, −1.6), respectively; therefore, missing two basal or four bolus doses would decrease TIR by >5%. Smart pen engagement was associated positively with glycemic outcomes. CONCLUSIONS: This combined analysis of real-world smart pen and CGM data showed that missing two basal or four bolus insulin doses over a 14-day period would be associated with a clinically relevant decrease in TIR. Smart insulin pens provide valuable insights into treatment injection behaviors.
5 November 2023 in Diabetes, Obesity and Metabolism
Aim: To evaluate whether both bolus insulin injection frequency and smart pen engagement were associated with changes in glycaemic control, using real‐world data from adults with type 1 diabetes (T1D). Materials and Methods: Adults using a smart pen (NovoPen 6) to administer bolus insulin (fast‐acting insulin aspart or insulin aspart) alongside continuous glucose monitoring were eligible for inclusion. Smart pen engagement was characterized by number of days with pen data uploads over the previous 14 days. Glycaemic control was evaluated by analysing glucose metrics. Results: Overall, data from 1194 individuals were analysed. The number of daily bolus injections was significantly associated with time in range (TIR; 3.9‐10.0 mmol/L [70‐180 mg/dL]; P < 0.0001). Individuals administering, on average, three daily bolus insulin injections had an estimated 11% chance of achieving >70% TIR. The probability of achieving >70% TIR increased with the mean number of daily bolus injections. However, the percentage of TIR was lower on days when individuals administered higher‐than‐average numbers of injections. The observed mean number of daily bolus injections administered across the study population was lower than the optimal number required to reach glycaemic targets (4.8 injections vs. 6‐8 injections). Smart pen engagement was significantly associated with improved TIR. Conclusions: Glycaemic control was associated with daily bolus insulin injection frequency and smart pen engagement. A treatment regimen combining an optimal bolus injection strategy, and effective smart pen engagement, may improve glycaemic control among adults with T1D.
28 August 2025 in Diabetes, Obesity and Metabolism
Aims: This observational study investigated changes in glycaemic control in people living with diabetes after initiating a connected insulin pen to administer their bolus insulin in routine clinical practice. Materials and methods: Data were collected from adults (≥18 years) with insulin‐treated diabetes who were using a continuous glucose monitoring (CGM) device and started administering bolus insulin using a connected insulin pen. Key glycaemic outcomes were time in range (TIR; 3.9–10.0 mmol/L), time above range (TAR; >10.0 mmol/L), and time below range (TBR; <3.9 and <3.0 mmol/L) in the overall population and for subgroups by country and by baseline TIR for individuals with 3 months of baseline CGM data. Results: Data were included from 86 133 individuals with a mean (standard deviation) age of 43.7 (15.7) years. There were small but statistically significant increases from baseline in TIR at month 3 (1.5%‐points), month 6 (1.4%‐points) and month 12 (1.1%‐points), and statistically significant decreases from baseline in TAR and TBR (<3.9 and <3.0 mmol/L) at month 3, month 6 and month 12. Increases in TIR were largest for those with the lowest baseline TIR (3‐month baseline average of <40% TIR). Increases in TIR were largest in Austria, with an increase in TIR of 4.7% at month 3. Conclusions: These real‐world data show that glycaemic outcomes improved after connected insulin pen initiation, especially in individuals with the highest unmet need (i.e., lowest baseline TIR). Combining a connected insulin pen with additional support, such as app‐based training or education, may further improve glycaemic control.